Improving outcomes through the use of surgical sealants for anastomotic sealing during cardiovascular surgery.

The continued need to minimize blood product usage both during and after cardiac surgical procedures has been challenged by a changing patient population, and most recently by the withdrawal of the antifibrinolytic aprotinin (Trasylol, Bayer Pharmaceuticals, West Haven, CT, USA) from the market. To meet these challenges, a variety of topical hemostatic tools have continued to emerge in the surgical armamentarium. These include hemostatic agents, adhesives, and sealants designed to control perioperative bleeding and decrease blood product utilization. Optimal application of novel topical adjuncts can be limited due to the lack of clarity on how to differentiate between these adjunctive hemostatic products and their appropriate uses. This paper will review the classes of these products, how and where such products can be used during cardiovascular surgery for achieving hemostasis, and the potential for improved outcomes through the appropriate selection and use of these agents.

Minimally invasive surgical ablation of atrial fibrillation: the thoracoscopic box lesion approach.

BACKGROUND: Atrial fibrillation is the most common cardiac rhythm disturbance and is associated with increased morbidity and mortality. It is often found in association with structural heart disease; however, lone atrial fibrillation is not uncommon. Potentially, these patients are ideal candidates for a minimally invasive thoracoscopic approach for the surgical treatment of atrial fibrillation. METHODS: From August 2003 through February 2006, 100 drug-resistant symptomatic patients with lone atrial fibrillation underwent thoracoscopic off-pump closed-chest epicardial ablation using the FLEX 10 AFx Microwave Ablation System (Guidant, Indianapolis, IN, USA). There were 66 men (66.0%) and 34 women (34.0%), with a mean age of 60.9 +/- 9.8 (range 37-81) years. Mean duration of atrial fibrillation was 72.4 +/- 79.5 (range 6-480) months. Sixty-four patients (64.0% had paroxysmal, 11 (11.0%) had persistent and 25 (25.0%) had permanent atrial fibrillation. RESULTS: There were no hospital deaths. Postoperative in-hospital complications were minimal. Mean postoperative length of stay was 3.4 +/- 1.7 days. Cumulative follow-up was 2,106.3 (mean 23.1) patient months, with a maximum follow-up of 39.8 months. There were three late deaths (3.0%). In nine patients (9.0%), the thoracoscopic box lesion pulmonary vein isolation operation and subsequent electrophysiological intervention failed, and a Cox-Maze operation was performed. Follow-up was 100% complete, with 42.0% (37 of 88) patients in normal sinus rhythm. Two patients (2.3%) experienced a transient ischemic attack and two (2.3%) a cerebral vascular accident. Twenty-seven patients (30.7%) required electrophysiological intervention post procedure. Ten patients (11.4%) were on amiodarone and 48 (54.5%) were on coumadin at follow-up. CONCLUSION: Totally thoracoscopic surgical ablation for the treatment of atrial fibrillation is technically feasible and presents minimal risk to the patient. Clinical results with the application of microwave energy have been less than satisfactory, with no demonstrated electrical isolation of the pulmonary veins. Moreover, long-term relief from atrial fibrillation has not been achieved.

Left atrial reduction enhances outcomes of modified maze procedure for permanent atrial fibrillation during concomitant mitral surgery.

BACKGROUND: Success of the maze procedure after mitral operations with large left atria and permanent atrial fibrillation remains suboptimal. Current technique variations tend to obscure the decision-making algorithm in these patients. A single energy-source approach for the surgical management of patients with large left atria and permanent atrial fibrillation is presented. METHODS: From January 2003 to July 2005, 71 consecutive drug-resistant patients with permanent atrial fibrillation and left atrial enlargement who required mitral valve surgery underwent aggressive left atrial reduction combined with left-sided only irrigated radiofrequency unipolar maze. Left atrial dimensions were measured by transesophageal echo anterior-to-posterior leading edge-to-edge standardized protocol. There were 39 men (54.9%) and 32 women (45.1%), and their mean age was 71.9 +/- 9.5 years. Mean duration of atrial fibrillation was 49.3 +/- 58.0 months. RESULTS: All patients underwent left atrial reduction with identical Cox-maze III pulmonary vein and appendage isolation including mitral annular connection, followed by appendage suture closure. Left atrial size was reduced from 6.7 +/- 1.2 cm to 4.3 +/- 0.6 cm (p = 0.001). Mitral valve repair was performed in 55 patients (76.1%) and replacement in 17 (23.9%). The 30-day mortality was 4.2% (3/71). Postoperative length of stay was 8.8 +/- 5.7 days, with 56 (82.4%) of 68 patients discharged in normal sinus rhythm. P-wave sinus rhythm was 93.8% between 7 and 12 months and 92.0% for patients with 1 year or more of follow-up. CONCLUSIONS: Left atrial reduction combined with a left atrial only single energy-source radiofrequency maze procedure is an effective treatment for patients with permanent atrial fibrillation undergoing concomitant mitral operations.

Totally endoscopic ablation of lone atrial fibrillation: initial clinical experience.

BACKGROUND: Atrial fibrillation is the most common form of arrhythmia leading to hospital admission. Over 2.2 million Americans are affected by atrial fibrillation and approximately 160,000 new cases are identified annually. As the population continues to age, the number of patients will increase. AF is an incremental risk factor for death and stroke, and consumes billions of dollars in health care expenditures. METHODS: Between August 2003 and October 2004, 50 drug-resistant, symptomatic atrial fibrillation patients underwent thoracoscopic or robotic-assisted off-pump epicardial microwave ablation with the FLEX 10 device (Guidant, Indianapolis, IN). There were 35 men (70.0%) and 15 women (30.0%), mean age 59.1 years +/- 10.0 (range, 37-75 years). Mean duration of atrial fibrillation was 73.5 months +/- 82.3 (range, 5-480 months). Thirty-three patients (66.0%) had intermittent atrial fibrillation and 17 (34.0%) continuous. Intermittent patients had pulmonary vein isolation whereas continuous patients had additional right and left atrial lesions performed. Forty-six patients (92.0%) had endoscopic stapling of the left atrial appendage. RESULTS: There were no hospital deaths. Postoperative in-hospital complications were minimal with 2 patients (4.0%) experiencing diaphragmatic dysfunction. No patient required a permanent pacemaker implant. Mean postoperative length of stay was 3.7 +/- 2.2 days. Cumulative follow-up was 335.8 patient months, mean 7.6 months (range, 2.0-15.9 months). There was 1 late death (2.0%). In 5 patients (10.0%) the MicroMaze operation and subsequent electrophysiology intervention failed and a Cox-Maze III operation was performed. Follow-up was 100% complete with 79.5% (35 of 44) patients in normal sinus rhythm. CONCLUSIONS: Totally endoscopic closed-chest microwave ablation for treatment of intermittent and continuous atrial fibrillation is technically feasible and presents minimal risk to the patient. Initial results are impressive and demonstrate an enhanced quality of life and freedom from atrial fibrillation in drug-resistant symptomatic patients.